A phase i study of resminostat in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 6, 2015, Pages 1155-1161

  Kitazono, Satoru ^a   Fujiwara, Yutaka ^a   Nakamichi, Shinji ^a   Mizugaki, Hidenori ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Yamada, Yasuhide ^a   Inukai, Eri ^b   Nakamura, Osamu ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Histone deacetylase; Phase I; Resminostat; Solid tumor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HISTONE DEACETYLASE 4; RESMINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SULFONAMIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENZYME ACTIVITY; ENZYME INHIBITION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HALF LIFE TIME; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPOALBUMINEMIA; JAPANESE (PEOPLE); LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PANCREAS CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; VOMITING; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SULFONAMIDES;

EID: 84929705286     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2741-8     Document Type: Article

References (21)

1. Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3:5
2. Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545-579
3. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019
4. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
5. Arts GJ, Langemeijer E, Tissingh R et al (2003) Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res 13:2325-2332
6. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13:673-691
7. Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47-60
8. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RF, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163
9. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247-1252
10. Mann BS, Johnson JR, He K et al (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13:2318-2322
11. Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27:5410-5417
12. Piekarz RL, Frye R, Prince HM et al (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117:5827-5834
13. Pohlman B, Advani R, Duvic M et al (2009) Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood 6:s379
14. Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P (2010) The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 149:518-528
15. Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193
16. Brunetto AT, Ang JE, Lal R et al (2013) First-in-human, pharmacokinetic and pharmacodynamic phase I study of resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 19:5494-5504
17. Marsoni S, Damia G, Camboni G (2008) A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3:164-171
18. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468
19. Kristeleit R, Fong P, Aherne GW, de Bono J (2005) Histone deacetylase inhibitors: emerging anticancer therapeutic agents? Clin Lung Cancer 7:S19-S30
20. Shah MH, Binkley P, Chan K et al (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12:3997-4003
21. Molife R, Fong P, Scurr M, Judson I, Kaye S, de Bono J (2007) HDAC inhibitors and cardiac safety. Clin Cancer Res 13:1068